PepGen Inc. PEPG
PepGen Inc. (Nasdaq: PEPG) is a rare genetic drug developer. Its lead program, PGN-EDODM1, is in Phase 2 for Myotonic dystrophy type 1 (DM1). Its next catalyst on record is PGN-EDODM1 FREEDOM2: Data from 10 mg/kg dose cohort (November 2026).
Upcoming catalysts
- November 2026PGN-EDODM1 FREEDOM2 — Data from 10 mg/kg dose cohort
we expect to report data from this cohort in November, 2026
Next further out: PGN-EDODM1 FREEDOM2 — Results from 12.5 mg/kg cohort (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PGN-EDODM1 | Myotonic dystrophy type 1 (DM1) | oligonucleotide-other | Phase 2 |
Recent results and decisions
- Aug 6, 2026positive PGN-EDODM1 5 mg/kg multiple-dose cohort in FREEDOM2 showed mean splicing correction of 22.9% (excluding outlier) and favorable safety with all adverse events mild or moderate.
PGN-EDODM1 was generally well-tolerated; all AEs were mild or moderate in severity, with no SAEs or cumulative toxicity with repeat dosing observed
Filing - Aug 6, 2026started DSMB recommends advancement into the highest dose cohort (12.5 mg/kg) of FREEDOM2-DM1 study following safety review.
DSMB recommends advancement of PGN-EDODM1 into the highest dose cohort in the FREEDOM2-DM1 study
Filing - May 12, 2026completed enrollment FREEDOM2 10 mg/kg MAD cohort fully enrolled.
The Company has fully enrolled the 10 mg/kg MAD cohort of FREEDOM2.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.